[Efficacy and safety of active immunotherapy in HIV-infected adults. Therapeutic vaccines against HIV.]

Škodová M, Llanos Méndez A
Record ID 32013000369
Spanish
Authors' recommendations: Currently, the only effective therapy for controlling HIV infection is highly active antiretroviral therapy consisting of the use of combination of three drugs with different mechanisms of action. The active immunotherapy or therapeutic vaccination against HIV is based on the administration of substances able to induce, encourage and/or strengthen the body's immune response to HIV in order to get a better control of the infection. Therapeutic vaccines in advanced stages of research are: viral vector vaccines (ALVAC-HIV; Adv5), inactivated whole virus vaccines (Remune), virus-like particles vaccines (p24VPL) and subunit vaccines (VaxSyn). We conducted a systematic literature review which recovered 3 synthesis reports and 12 controlled clinical trials. The aim of all the trials was to evaluate the immunogenicity and the security of therapeutic vaccines for HIV. All the vaccines were compared to placebo and designed as parallel groups. The methodological quality of selected studies was adequate or high in most randomized clinical trials included. However, interventions, tests to measure outcomes and the criteria used to define the adverse reactions were not homogeneous in the studies, making it difficult to compare the results. The results showed that the vaccines produced an immune response activation and lymphoproliferative response of limited duration, although it was not possible to assess the clinical relevance of these changes. The vaccines were generally safe and well tolerated by the participants of the studies. Any economic evaluation of active immunotherapy was not found.
Details
Project Status: Completed
URL for project: https://www.aetsa.org/publicacion/eficacia-y-seguridad-de-la-inmunoterapia-activa-en-adultos-infectados-por-el-vih-vacunas-terapeuticas-contra-el-vih/
Year Published: 2011
URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2011_2_4_InmunoterapiaVIH.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Immunotherapy, Active
  • AIDS Vaccines
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.